Advertisement

Breast Cancer Research and Treatment

, Volume 32, Issue 2, pp 229–233 | Cite as

Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer

  • L. Seymour
  • W. R. Bezwoda
Brief comunication

Abstract

Previous studies suggest a prognostic role for PDGF in patients with breast cancer, with patients with high plasma PDGF levels or positive response to therapy. We have examined a further 58 patients with advanced breast cancer for the presence of tissue PDGF immunostaining. Patients displaying positive tissue immunostaining for PDGF had a highly significant shorter survival (p = 0.002) than patients with no immunostaining. In addition PDGF positive patients treated with combination chemotherapy had a significantly lower response rate (p = 0.05) than PDGF negative patients. These results confirm our previous findings that PDGF may be an important indicator of shortened survival and treatment failure in patients with advanced breast cancer.

Key words

platelet derived growth factor PDGF breast cancer immunohistochemistry prognosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Ariad S, Seymour L, Bezwoda WR: Platelet derived growth factor (PDGF) in plasma of patients with breast cancer: correlation with stage and rate of progression. Breast Cancer Res Treat 20: 11–17, 1991Google Scholar
  2. 2.
    Seymour L, Dajee D, Bezwoda WR: Tissue platelet derived growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 26: 247–252, 1993Google Scholar
  3. 3.
    Seymour L, Dajee D, Bezwoda WR: Tissue platelet derived growth factor (PDGF) predicts for shortened survival and treatment failure in advanced breast cancer. Breast Cancer Res Treat 26: 247–252, 1993Google Scholar
  4. 4.
    Seymour L, Meyer K, Esser J, MacPhail AP, Behr A, Bezwoda WR: Estimation of PR and ER by immunocytochemistry in breast cancer. Am J Clin Path 94: 35–40, 1990Google Scholar
  5. 5.
    Seymour L, Bezwoda WR, Meyer K: Tumour factors predicting for prognosis in metastatic breast cancer. Cancer 66: 2390–2394, 1990Google Scholar
  6. 6.
    Hayward JL, Rubens RD, Carbone PP, Heuson JC, Kumaoka S, Segaloff A: Assessment of response to therapy in advanced breast cancer. Br J Cancer 35: 292–298, 1977Google Scholar
  7. 7.
    Heidaran MA, Beeler JF, Yu J-C, Ishibashi T, LaRochelle WJ, Pierce JH, Aaronson SA: Differences in substrate specificities of α and β platelet derived growth factor (PDGF) receptors. J Biol Chem 268: 9287–9295, 1993Google Scholar
  8. 8.
    Fretto LJ, Snape AJ, Tomlinson JE, Seroogy JJ, Wolf DL, LaRochelle WJ, Giese NA: Mechanism of platelet derived growth factor (PDGF) AA, AB, and BB binding to α and β PDGF receptor. J Biol Chem 268: 3625–3631, 1993Google Scholar
  9. 9.
    Slamon DJ, DeKernion JB, Verma IM, Cline MJ: Expression of cellular oncogenes in human malignancies. Science 224: 256–259, 1984Google Scholar
  10. 10.
    Leal F, Williams L, Robbins K, Aaronson S: Evidence that the v-sis gene product transforms by interaction with the receptor for PDGF. Science 230: 327–330, 1985Google Scholar
  11. 11.
    Fleming TP, Matsui T, Heidaran MA, Molloy CJ, Artrip J, Aaronson SA: Demonstration of an activated Platelet Derived Growth Factor autocrine pathway and its role in human tumour cell proliferationin vitro. Oncogene 7: 1355–1359, 1992Google Scholar
  12. 12.
    Silver BJ: Platelet Derived Growth Factor in human malignancy. Biofactors 3: 217–227, 1992Google Scholar
  13. 13.
    Lokeshwar VB, Huang SS, Huang JS: Intracellular turnover, novel secretion, and mitogenically active intracellular forms of v-sis gene product in simian sarcoma virus-transformed cells. Implications for intracellular loop autocrine transformation. J Biol Chem 265: 1665–1675, 1990Google Scholar
  14. 14.
    Battegay EJ, Raines EW, Selfert RA, Bowen-Pope DF, Ross R: TGF-β induces bimodal proliferation of connective tissue cells via complex control of an autocrine loop. Cell 63: 515–524, 1990Google Scholar
  15. 15.
    Haberstroh U, Zahner G, Disser M, Thaiss F, Wolf G, Stahl RAK: TGF-β stimulated rat mesangial cell proliferation in culture role of PDGF β-receptor expression. Am J Physiol 264: F199-F205, 1993Google Scholar
  16. 16.
    Behl C, Bogdahn U, Winckler J, Apfel R, Brysch W, Schlingensiepen K-H: Autoinduction of Platelet Derived Growth Factor (PGDF) A chain mRNA expression in a human malignant melanoma cell line and growth inhibitory effects of PDGF-A chain mRNA-specific antisense molecules. Biochem Biophys Res Comm 193: 744–751, 1993Google Scholar
  17. 17.
    Van de Meeren A, Seddon MB, Betsholtz CA, Lechner JF, Gerwin BI: Tumorigenic conversion of human mesothelioma cells as a consequence of Platelet Derived Growth Factor A chain overexpression. Am J Respir Cell Mol Biol 8: 214–221, 1993Google Scholar
  18. 18.
    Langerak AW, Dirks RP, Versnel MA: Splicing of the Platelet Derived Growth Factor A chain mRNA in human malignant mesothelioma cell lines. Eur J Biochem 208: 589–596, 1992Google Scholar
  19. 19.
    Elliott B, Ostman A, Westermark B, Rubin K: Modulation of growth factor responsiveness of murine mammary carcinoma cells by cell matrix interactions: Correlation of cell proliferation and spreading. J Cell Physiol 152: 292–301, 1992Google Scholar
  20. 20.
    Taverna D, Groner B, Hynes NE: Epidermal Growth Factor Receptor, Platelet Derived Growth Factor Receptor and c-erbB-2 receptor activation all promote growth but have distinctive effects upon mouse mammary epithelial cell differentiation. Cell Growth Differ 2: 145–154, 1991Google Scholar
  21. 21.
    Bronzert DA, Bates SE, Sheridan JP, Lindsey R, Valverius EM, Stampfer MR, Lippman ME, Dickson RB: Transforming Growth Factor-β induces Platelet Derived Growth Factor (PDGF) messenger RNA and PDGF secretion while inhibiting growth in normal human mammary epithelial cells. Mol Endocrinol 4: 981–989, 1990Google Scholar
  22. 22.
    Lippman ME, Dickson RB, Gelmann EP, Rosen N, Knabbe C, Bates S, Bronzert D, Huff K, Kasid A: Growth regulation of human breast cancer occurs through regulated growth factor secretion. J Cell Biochem 35: 1–16, 1987Google Scholar
  23. 23.
    Bronzert DA, Pantazis P, Antoniades HN, Kasid A, Davidson N, Dickson RB, Lippman ME: Synthesis and secretion of platelet derived growth factor by human breast cancer cell lines. Proc Natl Acad Sci 84: 5763–5767, 1987Google Scholar
  24. 24.
    Rakowicz-Szulczynska EM, Koprowski H: Expression of A-type PDGF receptor in cytoplasm of tumor cell lines synthesising PDGF. Exp Mol Pathol 51: 171–178, 1989Google Scholar
  25. 25.
    Ginsburg E, Vonderhaar BK: Stimulation of growth of human breast cancer cells (T47D) by Platelet Derived Growth Factor. Cancer Lett 58: 137–144, 1991Google Scholar
  26. 26.
    Ariad S, Seymour L, Bezwoda WR: Platelet derived growth factor (PDGF) in plasma of patients with breast cancer: correlation with stage and rate of progression. Breast Cancer Res Treat 20: 11–17, 1991Google Scholar
  27. 27.
    Tingstrom A, Reuterdahl C, Lindahl P, Heldin C-H, Rubin K: Expression of Platelet Derived Growth Factor-β receptors on human fibroblasts. J Immunol 148: 546–554, 1992Google Scholar
  28. 28.
    Wellstein A, Lupu R, Zugmaier G, Flamm SL, Cheville AL, Delli Bovi P, Basilico C, Lippman ME, Kern FG: Autocrine growth stimulation by secreted Kaposi fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth Differ 1: 63–71, 1990Google Scholar
  29. 29.
    Funa K, Papanicolaou V, Juhlin C, Rastad J, Akerstrom G, Heldin C-H, Oberg K: Expression of Platelet Derived Growth Factor β-receptors on stromal tissue cells in human carcinoid cells. Cancer Res 50: 748–753, 1990Google Scholar
  30. 30.
    Bissell MJ, Hall HG, Parry G: How does the extracellular matrix direct gene expression? J Theor Biol 99: 31–68, 1982Google Scholar
  31. 31.
    Brooks RF, Howard M, Leake DS, Riddle PN: Failure of Platelet Derived Growth Factor plus insulin to stimulate sustained proliferation of Swiss 3T3 cells. Requirement for hydrocortisone, prostaglandin E, lipoproteins, fibronectin and an unidentified component derived from serum. J Cell Sci 97: 71–78, 1990Google Scholar
  32. 32.
    Golombick T, Dajee D, Bezwoda WR: Cell extracellular matrix interactions 2: Extracellular matrix structure is important for growth factor localisation and function. (In press)Google Scholar

Copyright information

© Kluwer Academic Publishers 1994

Authors and Affiliations

  • L. Seymour
    • 1
  • W. R. Bezwoda
    • 1
  1. 1.Division of Clinical Haematology and Medical Oncology, Department of MedicineUniversity of the WitwatersrandJohannesburgSouth Africa

Personalised recommendations